Li Kang (Taiwan) Performance
| 6242 Stock | TWD 44.60 0.20 0.45% |
Li Kang has a performance score of 3 on a scale of 0 to 100. The company owns a Beta (Systematic Risk) of -0.0046, which conveys not very significant fluctuations relative to the market. As returns on the market increase, returns on owning Li Kang are expected to decrease at a much lower rate. During the bear market, Li Kang is likely to outperform the market. Li Kang Biomedical at this time owns a risk of 1.72%. Please verify Li Kang Biomedical market risk adjusted performance, semi deviation, coefficient of variation, as well as the relationship between the mean deviation and downside deviation , to decide if Li Kang Biomedical will be following its current price history.
Risk-Adjusted Performance
Insignificant
Weak | Strong |
Compared to the overall equity markets, risk-adjusted returns on investments in Li Kang Biomedical are ranked lower than 3 (%) of all global equities and portfolios over the last 90 days. In spite of fairly stable basic indicators, Li Kang is not utilizing all of its potentials. The latest stock price fuss, may contribute to near-short-term losses for the sophisticated investors. ...more
| Begin Period Cash Flow | 98.1 M | |
| Total Cashflows From Investing Activities | 12.2 M |
6242 |
Li Kang Relative Risk vs. Return Landscape
If you would invest 4,285 in Li Kang Biomedical on December 23, 2024 and sell it today you would earn a total of 175.00 from holding Li Kang Biomedical or generate 4.08% return on investment over 90 days. Li Kang Biomedical is generating 0.0841% of daily returns and assumes 1.7172% volatility on return distribution over the 90 days horizon. Simply put, 15% of stocks are less volatile than 6242, and 99% of all equity instruments are likely to generate higher returns than the company over the next 90 trading days. Expected Return |
| Risk |
Li Kang Market Risk Analysis
Today, many novice investors tend to focus exclusively on investment returns with little concern for Li Kang's investment risk. Standard deviation is the most common way to measure market volatility of stocks, such as Li Kang Biomedical, and traders can use it to determine the average amount a Li Kang's price has deviated from the expected return over a period of time. It is calculated by determining the expected price for the established period and then subtracting this figure from each price point. The differences are then squared, summed, and averaged to produce the variance.
Sharpe Ratio = 0.049
| Best Portfolio | Best Equity | |||
| Good Returns | ||||
| Average Returns | ||||
| Small Returns | ||||
| Cash | Small Risk | 6242 | High Risk | Huge Risk |
| Negative Returns |
Estimated Market Risk
| 1.72 actual daily | 15 85% of assets are more volatile |
Expected Return
| 0.08 actual daily | 1 99% of assets have higher returns |
Risk-Adjusted Return
| 0.05 actual daily | 3 97% of assets perform better |
Based on monthly moving average Li Kang is performing at about 3% of its full potential. If added to a well diversified portfolio the total return can be enhanced and market risk can be reduced. You can increase risk-adjusted return of Li Kang by adding it to a well-diversified portfolio.
Li Kang Fundamentals Growth
6242 Stock prices reflect investors' perceptions of the future prospects and financial health of Li Kang, and Li Kang fundamentals are critical determinants of its market performance. Overall, investors pay close attention to revenue and earnings growth, profit margins, and debt levels. These fundamentals can have a significant impact on 6242 Stock performance.
| Return On Equity | 0.19 | |||
| Return On Asset | 0.12 | |||
| Profit Margin | 0.16 % | |||
| Operating Margin | 0.19 % | |||
| Current Valuation | 1.05 B | |||
| Shares Outstanding | 23.31 M | |||
| Price To Earning | 15.32 X | |||
| Price To Book | 2.30 X | |||
| Price To Sales | 1.94 X | |||
| Revenue | 386.97 M | |||
| EBITDA | 76.83 M | |||
| Cash And Equivalents | 187.44 M | |||
| Cash Per Share | 8.04 X | |||
| Total Debt | 24.59 M | |||
| Debt To Equity | 0.06 % | |||
| Book Value Per Share | 23.12 X | |||
| Cash Flow From Operations | 60.45 M | |||
| Earnings Per Share | 4.16 X | |||
| Total Asset | 616.07 M | |||
About Li Kang Performance
Evaluating Li Kang's performance through its fundamental ratios, provides valuable insights into its operational efficiency and profitability. For instance, if Li Kang has a high ROA and ROE, it suggests that the company is efficiently using its assets and equity to generate substantial profits, making it an attractive investment. Conversely, if Li Kang has a low ROA and ROE, it may indicate underlying issues in asset and equity management, signaling a need for operational improvements. Please also refer to our technical analysis and fundamental analysis pages.
Li Kang Biomedical Co., Ltd. manufactures and sells supplement, cosmeceutical, and hygienic drinks. Li Kang Biomedical Co., Ltd. was founded in 1982 and is based in Tainan City, Taiwan. LI KANG operates under Travel Services classification in Taiwan and is traded on Taiwan OTC Exchange. It employs 123 people.Things to note about Li Kang Biomedical performance evaluation
Checking the ongoing alerts about Li Kang for important developments is a great way to find new opportunities for your next move. Stock alerts and notifications screener for Li Kang Biomedical help investors to be notified of important events, changes in technical or fundamental conditions, and significant headlines that can affect investment decisions.| About 72.0% of the company shares are owned by insiders or employees |
- Analyzing Li Kang's financial statements, including its income statement, balance sheet, and cash flow statement, helps in understanding its overall financial health and growth potential.
- Getting a closer look at valuation ratios like price-to-earnings (P/E) ratio, price-to-sales (P/S) ratio, and price-to-book (P/B) ratio help in understanding whether Li Kang's stock is overvalued or undervalued compared to its peers.
- Examining Li Kang's industry or sector and how it is performing can give you an idea of its growth potential and how it is positioned relative to its competitors.
- Evaluating Li Kang's management team can have a significant impact on its success or failure. Reviewing the track record and experience of Li Kang's management team can help you assess the Company's leadership.
- Pay attention to analyst opinions and ratings of Li Kang's stock. These opinions can provide insight into Li Kang's potential for growth and whether the stock is currently undervalued or overvalued.
Additional Tools for 6242 Stock Analysis
When running Li Kang's price analysis, check to measure Li Kang's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Li Kang is operating at the current time. Most of Li Kang's value examination focuses on studying past and present price action to predict the probability of Li Kang's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Li Kang's price. Additionally, you may evaluate how the addition of Li Kang to your portfolios can decrease your overall portfolio volatility.